飞一般的亮哥
Lv6
2180 积分
2023-08-25 加入
-
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
2天前
已完结
-
A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia
1个月前
已完结
-
Recent progress in ITP treatment
1个月前
已完结
-
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
1个月前
已完结
-
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
-
IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
2个月前
已完结
-
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator– and Placebo-Controlled Study
2个月前
已完结
-
Determination of faropenem in human plasma and urine by liquid chromatography–tandem mass spectrometry
4个月前
已完结
-
Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant
6个月前
已完结
-
P272 NMD670, a novel first-in-class muscle ClC-1 inhibitor, improves symptoms of myasthenia gravis: a randomized, single-dose, double-blind, placebo-controlled study
9个月前
已完结